Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
前收盘价
US$339.09
−US$2.16 · -0.63%
盘中时间采用ET。市场数据可能有所延迟。
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
日内区间
当前US$339.09
52周区间
当前US$339.09
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
91
深度低估
情绪
60
多空交织
风险
23
中等风险
动量
43
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
日内区间
当前US$339.09
52周区间
当前US$339.09
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 3373.97亿 USD | 3213.33亿 USD | 2939.59亿 USD | 2621.73亿 USD | 2385.87亿 USD |
| 销货成本 | 3235.29亿 USD | 3111.91亿 USD | 2852.57亿 USD | 2544.17亿 USD | 2309.86亿 USD |
| 毛利 | 138.68亿 USD | 101.42亿 USD | 87.01亿 USD | 77.56亿 USD | 76.01亿 USD |
| 销售、一般及管理费用 | 80.78亿 USD | 64.94亿 USD | 56.61亿 USD | 53.1亿 USD | 48.49亿 USD |
| 营业费用 | 99.38亿 USD | 64.94亿 USD | 56.61亿 USD | 53.1亿 USD | 48.49亿 USD |
| 利息收入 | — | 1.28亿 USD | 9169.1万 USD | 4671.9万 USD | 2130.9万 USD |
| 利息支出 | 4.9亿 USD | 4.2亿 USD | 2.49亿 USD | 2.76亿 USD | 2.32亿 USD |
| 折旧和摊销 | 10.45亿 USD | 10.68亿 USD | 11.19亿 USD | 9.81亿 USD | 7.1亿 USD |
| 营业利润 | 39.3亿 USD | 36.48亿 USD | 30.4亿 USD | 24.47亿 USD | 27.52亿 USD |
| 净利润 | 34.84亿 USD | 15.54亿 USD | 15.09亿 USD | 17.45亿 USD | 16.99亿 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$364
上涨空间 7.35%年度分割调整后的每股现金分配。
US$2.25
2025年(完整年度)-47.9% 自从 2021
2026年(部分年度):US$2.46
US$4.32
2,021
US$1.865
2,022
US$1.965
2,023
US$2.08
2,024
US$2.25
2,025
US$2.46
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年11月13日 | US$0.66Quarterly | 2026年11月13日 | 2026年11月30日 |
股息 | 2026年8月14日 | US$0.60Quarterly | 2026年8月14日 | 2026年8月31日 |
股息 | 2026年5月15日 | US$0.60Quarterly | 2026年5月15日 | 2026年6月1日 |
股息 | 2026年2月13日 | US$0.60Quarterly | 2026年2月13日 | 2026年3月2日 |
股息 | 2025年11月14日 | US$0.60Quarterly | 2025年11月14日 | 2025年12月1日 |
股息 | 2025年8月15日 | US$0.55Quarterly | 2025年8月15日 | 2025年9月3日 |
除息 2026年11月13日
US$0.66
Quarterly
2026年11月13日登记 · 支付日 2026年11月30日
除息 2026年8月14日
US$0.60
Quarterly
2026年8月14日登记 · 支付日 2026年8月31日
除息 2026年5月15日
US$0.60
Quarterly
2026年5月15日登记 · 支付日 2026年6月1日
除息 2026年2月13日
US$0.60
Quarterly
2026年2月13日登记 · 支付日 2026年3月2日
除息 2025年11月14日
US$0.60
Quarterly
2025年11月14日登记 · 支付日 2025年12月1日
除息 2025年8月15日
US$0.55
Quarterly
2025年8月15日登记 · 支付日 2025年9月3日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T1258.25亿0.11%119.93万亿 JPY0.09%JP¥113,700-3.19%
Vanguard S&P 500 ETFVOO16.78亿0.10%1万亿 USD0.03%US$635.54-3.41%
Vanguard Morningstar Total Stock Market ETFVTI15.03亿0.08%6893亿 USD0.03%US$340.02-3.52%
Vanguard Morningstar Mid-Cap ETFVO12.81亿0.57%1074亿 USD0.03%US$76.25-2.22%
iShares Core S&P 500 ETFIVV8.71亿0.11%8034.1亿 USD0.03%US$693.71-3.52%
State Street SPDR S&P 500 ETFSPY7.94亿0.11%7563.79亿 USD0.09%US$689.81-3.64%
Vanguard Morningstar Value ETFVTV5.77亿0.22%1959亿 USD0.03%US$214.22-1.62%
State Street Health Care Select Sector SPDR ETFXLV4.75亿1.01%469.2亿 USD0.08%US$177.24-0.12%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLVAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。